Background {#Sec1}
==========

Trigeminal neuralgia (TN) is severe and recurring pain distributed unilaterally along a branch of the trigeminal nerve. \[[@CR1], [@CR2]\] TN can be triggered by brushing the teeth, washing the face, drinking liquids, or shaving. Patients become fearful of performing these life activities, in anticipation of long-lasting stabbing pain. TN patients may display a haggard facial expression and depressive mood, as their quality of life and ability to work is compromised. The most common treatment is anti-epileptics such as carbamazepine and oxcarbazepine. However, these medications may have to be discontinued due to intolerable side effects. Neurosurgical interventions remain debatable for safety and efficacy concerns \[[@CR3]\].

Botulinum toxin type A (BTX-A) is an exotoxin released by the gram-positive bacterium *Clostridium botulinum*. Its initial medicinal use was in the management of blepharospasm and hemifacial spasm \[[@CR4]\]. In recent years, BTX-A has been used for the relief of chronic migraine and many other types of headache \[[@CR5]--[@CR8]\]. The application of BTX-A to relieve TN was first reported in 2002, and its safety and effectiveness was later confirmed by series studies \[[@CR9]--[@CR19]\]. These findings suggest that local intradermal or submucosal injections of BTX-A may be a promising therapy for TN.

In 2009, our group initiated a study of TN treatment using BTX-A, and a clinical database was established. Through several clinical trials, our group has shown that BTX-A can provide long-lasting relief of TN symptoms, with only mild or moderate side effects \[[@CR10], [@CR16]--[@CR18]\]. However, before clinical application of BTX-A for TN treatment can become routine, a standardized therapeutic regimen should be established. In particular, there is no consensus regarding dosage or treatment schedule, and relevant clinical trial data are scarce. In a randomized, double blind, placebo-controlled study in 2014, we reported that doses of 25 U or 75 U BTX-A were similar in short-term efficacy for treatment of TN \[[@CR17]\]. Since the efficacy could not be improved by simply increasing the dose, we asked whether the efficacy may change if the dosing time was extended. To answer this question, for the present study we conducted an open-label trial to compare the efficacy, safety, and tolerability of single or repeated administrations of BTX-A in patients with TN.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This is an open-label trial with an intended sample size of 100 patients. The trial was approved by the local ethics committee. Before treatment, each patient was counseled regarding the goal, procedure, and possible adverse reactions, and they were informed of the risk of transient attendant weakness and disfigurement produced by localized administration of BTX-A.

The patients were randomized into a single-dose or a repeated-dose group (*n* = 50, each). Patients in the single-dose group received a local BTX-A (70--100 U) injection at the site of pain. Patients assigned to the repeated-dose group received the initial treatment of BTX-A and then another injection 2 weeks later, with 50--70 U per time and a total dosage of 100--140 U. All the patients were followed for 6 months, and they had the freedom to withdraw from the study at any time. Patients who completed the entire 6-month follow-up were eligible for the final study analysis.

Study participants {#Sec4}
------------------

All the medical information from October 2012 to June 2015 was collected from the Department of Neurology, First Affiliated Hospital of Zhengzhou University. All the recruited patients had primary TN and received BTX-A treatment. The criteria for inclusion in the study were the following: underwent comprehensive physical examination and medical tests to exclude the existence of coagulopathy, or severe heart, liver, kidney, or other organ dysfunction; underwent coronal magnetic resonance imaging or computed tomography to rule out secondary TN; diagnosis of classical TN based on the current version of the International Classification of Headache Disorders (ICHD-II) \[[@CR20]\]; baseline TN-associated VAS score ≥ 6; and analgesics received before the study remained unchanged during the course of the study.

Patients with any of the following were excluded from the study: prior BTX-A treatment; comorbid diseases that may be exacerbated by BTX-A (e.g., myasthenia gravis, motor neuron disease, or Lambert-Eaton syndrome); infection or dermatosis at the injection site; receiving drugs with neuromuscular junction toxicity 1 week before BTX-A treatment (e.g. quinine, aminoglycosides or penicillamine); unstable psychiatric disease; history of drug abuse or addiction; pregnant, plans for pregnancy, or lactating; analgesic therapies begun at any time during the study.

Treatment {#Sec5}
---------

BTX-A (100 U of *Clostridium botulinum* type A neurotoxin complex, 5 mg gelatin, 25 mg dextran, and 25 mg saccharose) was obtained from Lanzhou Biological Products Institute (Lanzhou, China). All treatments were administered in a specially-designated treatment room, which is equipped with facilities to ensure safety in the event of severe reaction or emergency. During injections, the patients lay supine on a bed.

The BTX-A was dissolved in 2 mL of saline to 50 U/mL before use. The injections were administered intradermally, submucosally, or both, at the site of pain using a 1-mL syringe with a 0.45 × 16 mm needle. The injection depth was nearly 0.1 cm, and, for multiple site injection, 15-mm distance was set between injection sites. There were 15--25 injection sites in total, with 1.25--5 U at each site. For single injection patients, the total dosage of BTX-A were set within 70--100 U. While for patients receiving two times of BTX-A, the dosage was within 50--70 U each time.

Follow up and efficacy assessment {#Sec6}
---------------------------------

The patients were required to provide a daily diary of their pain symptoms, including provoking factors, frequency of TN attacks, severity of pain (according to an 11-point visual analogue scale, VAS) and adverse reaction. Prior to the first injection, patient demographics, gender, age, presence of trigger zone, side of involvement, and the nerve branch involved were also recorded. Follow-up visits were made every week during the first month after the injection, and once per month thereafter.

To determine the efficacy of treatment, during each follow-up visit the pain severity and attack frequency from baseline to endpoint, time until the drug treatment took effect, and the peak time and duration of drug efficacy were noted. A drug response was defined as ≥50% reduction in mean pain score from baseline to endpoint.

Safety assessment {#Sec7}
-----------------

Safety was measured according to the occurrence of adverse events, and recorded with date of onset, severity, duration, treatment required (if any), and outcome.

Statistical analysis {#Sec8}
--------------------

The quantitative data were expressed as mean ± standard deviation. Differences between independent groups were evaluated by means of a *t*-test. The chi-squared test was performed to assess differences in treatment responses. The data were analyzed using SPSS20.0 software. *P* \< 0.05 was considered a significant statistical difference.

Results {#Sec9}
=======

Patient disposition {#Sec10}
-------------------

After the 6-month follow-up period, 44 and 37 patients in the single-dose and repeated-dose groups, respectively, had completed the entire study (Table [1](#Tab1){ref-type="table"}). Nineteen patients loss due to patient drop out (The agreement stipulates that they may withdraw at any time) or incomplete follow up. The groups were well matched at baseline for age, gender, duration of symptoms, and side and nerve branch involved (*P \>* 0.05).Table 1Baseline demographic characteristics and clinical data of TN patients given single or repeated dose BTX-A^a^Single doseRepeated dose*P*Subjects, n4437Age, y^b^60.73 ± 10.8857.14 ± 10.390.056Disease course, mo ^b^73.50 ± 63.6350.46 ± 43.950.059GenderMale19 (43.2%)16 (43.2%)1Female25 (56.8%)21 (56.8%)SideLeft17 (38.6%)14 (37.8%)1Right27 (61.4%)23 (62.2%)Nerve branch15 (11.4%)3 (8.1%)0.324210 (22.7%)11 (29.7%)311 (25.0%)8 (21.6%)1, 28 (18.2%)3 (8.1%)1, 32 (4.5%)0 (0.0%)2, 38 (18.2%)10 (27.0%)1, 2, 30 (0.0%)2 (5.4%)ToothacheYes11 (25.0%)15 (40.5%)0.158No33 (75.0%)22 (59.5%)^a^Reported as n (%), unless indicated otherwise ^b^ y = year, mo = month

Efficacy results {#Sec11}
----------------

To investigate differences in treatment efficacy between the single- and repeated-dose groups, the rate of TN occurrence was determined before and after each dosing (Table [2](#Tab2){ref-type="table"}); results from the *t*-test indicated no significant difference between the single- and repeated-dose groups (*P* \> 0.05). The times to drug effect and peak efficacy times of the 2 groups were also statistically similar. However, the duration of efficacy in the single-dose group was significantly longer than that of the repeated-dose group (*P* = 0.032).Table 2Evaluation on the efficacy of single and repeated doses of BTX-ASingle doseRepeated dose*P* valueSubjects, *n*4437TN frequency, *n*Before treatment18.40 ± 24.8922.85 ± 28.260.454After treatment2.07 ± 3.623.19 ± 9.230.461Time to take effect, d8.51 ± 6.3710.08 ± 6.630.282Time to peak efficacy, d30.86 ± 18.9025.62 ± 16.250.189Efficacy maintenance, mo4.76 ± 1.733.87 ± 1.920.032*d* day, *mo* month

The drug response rates of the single- and repeated-dose groups (i.e., percent of patients with ≥50% reduction in mean pain score from baseline to endpoint) were not significantly different (*P \>* 0.05, Table [3](#Tab3){ref-type="table"})Table 3Response to treatment at follow-ups throughout the study, *n* (%)Single doseRepeated dose*P*Subjects, n44371 mo35 (79.5)31 (83.8)0.2022 mo40 (90.9)31 (83.8)0.1683 mo40 (90.9)31 (83.8)0.1684 mo35 (79.5)24 (64.9)0.0685 mo31 (70.5)23 (62.2)0.1376 mo27 (61.4)19 (51.4)0.119*mo* month

VAS score {#Sec12}
---------

At baseline, each group was well matched for severity of VAS scores (8.26 ± 1.68 and 7.98 ± 1.60 for the single- and repeated-dose groups, respectively; Table [4](#Tab4){ref-type="table"}). At each assessment after the BTX-A injection, the VAS scores of the 2 groups were similar (*P \>* 0.05, Fig. [1](#Fig1){ref-type="fig"}). These results suggest that, throughout the study, there was no significant difference in the efficacy between the 2 dosing modalities (*P* \> 0.05).Table 4VAS scores at baseline and during the 6-month follow-upTimeDose groupVAS*P*0wSingle7.99 ± 1.600.441Repeated8.27 ± 1.691wSingle4.40 ± 2.210.089Repeated5.45 ± 3.081moSingle2.54 ± 2.370.977Repeated2.52 ± 2.722moSingle1.66 ± 2.110.374Repeated2.15 ± 2.693moSingle1.59 ± 2.170.198Repeated2.36 ± 3.014moSingle2.02 ± 2.530.084Repeated3.23 ± 3.495moSingle2.42 ± 2.840.150Repeated3.48 ± 3.586moSingle3.02 ± 3.290.095Repeated4.32 ± 3.61*w* week, *mo* monthSingle dose, *n* = 44; repeated dose, *n* = 37 Fig. 1Monthly VAS scores of TN patients. Patients in the single- and repeated-dose groups were followed for 6 consecutive months after the first BTX-A injection. At each follow-up, the VAS scores of the 2 groups were comparable

Safety assessment {#Sec13}
-----------------

Adverse reactions of the patients in the 2 groups were mild to moderate, and therefore the safety profiles of both regimens were considered satisfactory (Table [5](#Tab5){ref-type="table"}). Rates of adverse reactions of the 2 groups were similar, both in duration and time to the appearance of these side effects (*P \>* 0.05).Table 5Adverse reactions associated with BTX-A treatmentSingle doseRepeated dose*P*Subjects, *n*4437Patients experiencing side effects, *n* (%)7 (15.9)7 (18.9)0.774Time before side effects, d2.22 ± 7.20422.405 ± 5.78050.904Duration of side effects, d7.068 ± 20.94118.703 ± 22.08930.734*d* day

Discussion {#Sec14}
==========

BTX-A is a *Clostridium botulinum*-derived exotoxin that has been used widely in cosmetology and for treating dysmyotonia \[[@CR16]\]. Recent years have seen an enormous interest in the application of BTX-A to relieve chronic migraine and other types of headache \[[@CR5]--[@CR8]\]. In addition, BTX-A has been used for neuropathic pain, including post-herpetic neuralgia \[[@CR21]\], diabetic neuropathic pain \[[@CR22], [@CR23]\], and occipital neuralgia \[[@CR24]\]. However, to date, no standardized dosing regimen has been established. We conducted this pilot study to evaluate the efficacy and safety of single-dose BTX-A compared with repeated-dose BTX-A in TN. We found during a 6-month follow-up that single and repeated dosing of BTX-A in TN patients have comparable efficacy and side effects.

Since 2002, there have been many reports concerning BTX-A treatment for TN \[[@CR9]--[@CR19]\]. Several randomized clinical studies have focused on efficacy and safety issues \[[@CR25]\]. These findings have triggered much interest in clarifying questions such as the optimal dose, duration of therapeutic efficacy, and common adverse reactions \[[@CR26]\]. Our group has also been working on determining the efficacy and safety of the clinical use of BTX-A \[[@CR10], [@CR16]--[@CR18]\].

The impetus for this study was our clinical experience that, in some TN patients showing poor responses to BTX-A, repeated dosing may lead to better pain relief. In an earlier 14-month follow-up study involving 88 patients with TN, we found that the duration of therapeutic effect (i.e., reduction in VAS scores) may be due mostly to the first injection of BTX-A \[[@CR16]\]. Therefore, we recommended a relatively low dose at the first injection, and, if necessary, an additional 1-to-3 doses to treat intractable TN, 2-to-4 weeks later.

However, we still wondered if repeated dosing conferred a therapeutic advantage over a single dose. Thus, we determined to perform the present pilot open-label trial to compare the efficacy and safety profiles of single or repeated doses of BTX-A. An important factor in our study design was that a medium dose (50--100 U) of BTX-A was used, because this is within the most common dosing range in our clinical practice. Moreover, a relatively larger dose was used in patients who received the repeated dose (100--140 U compared to 70--100 U in single dose group). Although our previous study indicated that such a difference in dosage may not influence efficacy and safety, at least in the short term, future studies are warranted to determine doses for single and repeated dosing regimens.

Our present study suggests that both the single and repeated dosing regimens were similar in frequency rates and severity of side effects. Thus, it is reasonable to suggest that the occurrence of adverse reactions is more relevant to the injection procedure. This may require more attention in future practice. For example, the orbicular muscle of the mouth should be avoided, and a reduced dose may be required at each injection site (e.g., 1.25--2.5 U/point).

The results of our study showed that repeated dosing of BTX-A did not contribute to improved clinical outcome in TN patients. Since repeated dosing is accompanied by increased cost and inconvenience, single dosing may be the best choice in management of TN. Nevertheless, for patients who respond poorly to the first injection, a second dosing may still be safely performed. Given the inherent limitation of this pilot study, a future study is anticipated to provide more comprehensive evaluation of the optimal BTX-A regimen for clinical management of TN.

Conclusions {#Sec140}
===========

The single- and repeated-dosing BTX-A regimens were largely comparable in efficacy and safety. This study suggests that repeated dosing has no advantage over single dosing of BTX-A for TN. Dosing should be adjusted for the individual patient.

Highlight {#Sec15}
---------

1\. The single- and repeated-dosing of BTX-A were comparable in efficacy and safety in TN.

2\. Repeated dosing has no advantage over single dosing of BTX-A for TN.
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